Tesamorelin
Proven for HIV-related belly fat; early evidence only for general fat loss.
A daily injection approved only for excess belly fat in adults with HIV. It is also sold and on the for fat loss, though its label says it is not for weight loss. A made by Theratechnologies, also called Egrifta WR and Egrifta SV.
What the evidence shows
Side effects and risks
Who should avoid it: Active cancer, pituitary disease or surgery, and pregnancy.
Athletes: Banned at all times (WADA class S2, growth-hormone-releasing factors).
How it works
- Where it acts
- Growth-hormone-releasing hormone receptors on the pituitary gland.
- What it changes
- The pituitary releases more of the body's own growth hormone in pulses, which raises IGF-1.
- What people notice
- Less deep belly fat over months in people with HIV-related fat build-up. Joint pain and swelling can occur.
How it is taken
Daily injection under the skin of the abdomen: 1.28 mg of the current Egrifta WR formulation. A prescriber checks IGF-1 and blood sugar during treatment.
Getting it in the United States
The legal route for Tesamorelin
Get a prescription from a licensed clinician. Fill it at a licensed pharmacy or through the maker's own direct service.
Prescription via specialty pharmacy
Egrifta WR is dispensed by specialty pharmacies on prescription, with insurer coverage varying. The maker runs a free support program with nurse training for patients switching formulations.
Routes people use for any peptide in the United States
Telehealth prescribing
Online clinics prescribe after a questionnaire, sometimes with no live doctor visit, and mail the drug. FDA moved in February 2026 to restrict mass-marketed compounded copies and claims that they are generic equivalents.
Risk: Thin medical screening. Compounded versions are not reviewed by FDA for quality.
Covers: Approved GLP-1 drugs, compounded semaglutide and tirzepatide
Source: GZERO Media, Apr 2026
Clinical trial enrolment
The only lawful way to get an unapproved peptide drug with medical monitoring. ClinicalTrials.gov lists eligibility, sites and phone numbers. Researchers note recruitment is hard when people can buy the drug on the gray market instead of risking placebo.
Risk: Possible placebo assignment, strict eligibility and travel to a study site.
Covers: Investigational peptide drugs still in development
Source: NIH, finding a clinical trial
Online grey-market vendors
Forbes reported a price tracker counting over 700 online vendors listing tesamorelin, though it is not cleared for compounding. Contents are unverified and users have reported severe allergic reactions.
Source: Forbes Brasil (Forbes feature by Iain Martin), 2026-09
Routes people use for any peptide in the United States
Compounding pharmacy with prescription
A clinician prescribes and a pharmacy compounds. Twelve peptides left the FDA do-not-compound category in April 2026 and a panel backed six in July, but they are not yet formally eligible. Pharmaceutical-grade ingredient is scarce.
Risk: Legal status is unsettled until FDA rulemaking ends. Pharmacies may use research-grade ingredient.
Covers: BPC-157, TB-500, KPV, MOTS-c, Semax, Epitalon and similar
Source: Frier Levitt, Apr 2026
Med spas and weight-loss clinics
Very common. Secret shoppers called 75 clinics and med spas in two states after shortages ended. 92 percent offered compounded semaglutide and 87 percent tirzepatide, often mixed with B vitamins to look custom.
Risk: Four of 23 suppliers lacked sterile compounding licenses and four had disciplinary records.
Covers: Compounded semaglutide and tirzepatide
Source: American Med Spa Association on JAMA Health Forum study, Jul 2026
Concierge and longevity doctors
Cash-pay physicians build peptide plans for wealthy clients. Reporting from San Francisco says some source from overseas channels, domestic research-use-only sellers or the few compounding pharmacies that will supply clinicians.
Risk: A doctor's involvement does not guarantee a pharmaceutical-grade product.
Covers: BPC-157, thymosin alpha-1, Selank, Semax, CJC-1295, ipamorelin, retatrutide
Source: San Francisco Standard, Sep 2025
Cross-border purchase or import
FDA says importing drugs for personal use is illegal in most cases but it may not object to small personal quantities in limited situations. Reporting also describes people travelling to Mexico for injections.
Risk: Packages can be seized. Product origin and cold-chain handling are hard to check.
Covers: Approved prescription peptides sold abroad
Source: FDA, personal importation
Routes people use for any peptide in the United States
Research-chemical websites
Sites sell vials marked for research or not for human consumption, with no prescription. FDA says some ship direct to consumers with dosing directions, and it has sent warning letters. Retatrutide exists only through this route or trials.
Risk: Unknown identity, strength and sterility. No pharmacist or prescriber involved.
Covers: Retatrutide, semaglutide, tirzepatide, BPC-157 and most unapproved peptides
Source: FDA, unapproved GLP-1 drugs page
Direct orders from Chinese factories
Buyers message factory sales agents and pay by crypto or payment app. A minimum order of about ten vials pushes people to buy in bulk and share. A blockchain analysis found US buyers were the largest source of funds.
Risk: Many of the same vendors list fentanyl precursors. Lab reports sent by sellers cannot be verified.
Covers: GLP-1 copies, melanotan II, BPC-157, TB-500, GHK-Cu, epitalon
Source: TRM Labs, Oct 2026
Chat groups and social sellers
Dealers are found through Telegram, WhatsApp, Discord and influencer discount codes. In a May 2026 survey of 1,000 US users, 14.5 percent bought this way and three quarters asked an AI chatbot for dosing.
Risk: 45 percent of social media buyers in that survey reported an emergency or urgent care visit for a reaction.
Covers: Retatrutide and other research-use-only peptides
Source: The Ethos, May 2026
This describes what people do. It is not advice. The decision is yours.
What users report
Recurring themes in public forum posts, unverified and with no comparison group.
Reported benefits
- Smaller waist after a few months
- Better sleep for some
Reported problems
- Joint aches, tingling hands, water retention
- Higher blood sugar readings
- Expensive; effect fades after stopping
Most reports come from people using it off-label, a group it was never tested in.
What experts and influencers say
Recorded views, not a survey or scientific consensus. Cautions may concern misuse or unapproved products. Statements are paraphrased; check each source for context.
Supportive expert view
Co-led an NIH-backed trial testing whether the drug, already known to cut belly fat in HIV, would also cut liver fat. The trial found it did.
Source: NIH news release, 2019-10
Steven GrinspoonWikipediaRecommends
Cautionary expert view
Calls the craze unfounded. He found no randomized human trial showing the advertised benefits for any of the unapproved peptides he reviewed, and warns about stacking several at once. He points to animal work in which TB-500 sped up dormant tumor growth and to a theoretical cancer concern with growth-hormone peptides and BPC-157. He treats the GLP-1 drugs as the well-studied exception.
Source: Eric Topol, "The Peptide Craze", Jul 2025, Associated Press, Nov 2025
Eric TopolWebsiteWarns against
See all views 8
Co-led an NIH-backed trial testing whether the drug, already known to cut belly fat in HIV, would also cut liver fat. The trial found it did.
Source: NIH news release, 2019-10
Steven GrinspoonWikipediaRecommends
Devoted a full episode in 2024 to how these peptides are thought to work and how people use them. He presents possible benefits for healing, growth hormone, sleep and libido, and also says most of the data comes from animals, that black-market products may be contaminated, and that anyone with a tumor or cancer concern should avoid peptides that promote growth or new blood vessels.
Source: Huberman Lab episode, 1 Apr 2024
Described it on his podcast as an approved option for HIV-related belly fat and preferred it over CJC-1295. Urged physician oversight.
Andrew HubermanInstagramMixed view
Calls the craze unfounded. He found no randomized human trial showing the advertised benefits for any of the unapproved peptides he reviewed, and warns about stacking several at once. He points to animal work in which TB-500 sped up dormant tumor growth and to a theoretical cancer concern with growth-hormone peptides and BPC-157. He treats the GLP-1 drugs as the well-studied exception.
Source: Eric Topol, "The Peptide Craze", Jul 2025, Associated Press, Nov 2025
Eric TopolWebsiteWarns against
Called it encouraging that a drug already approved for another HIV complication might also treat fatty liver disease in people with HIV.
Source: NIH news release, 2019-10
Anthony FauciWebsiteRecommends
Judges each peptide separately. He sees no use case for BPC-157: no human evidence, animal data mostly from one lab, and claims that keep widening. He is not a proponent of growth-hormone peptides such as CJC-1295, citing short studies and no long-term safety data. He says elamipretide makes sense only for Barth syndrome, that the risks of melanotan II probably outweigh a cosmetic tan, and that he stopped prescribing bremelanotide. He regards the GLP-1 drugs as clearly effective.
Peter AttiaInstagramMixed view
Told the European applicant that the data did not support a positive benefit-risk balance. The company then withdrew its Egrifta application, so the drug has no EU licence.
Source: EMA news, 2012-06
EMA human medicines committee (CHMP)SourceWarns against
Announced US availability of the weekly-mix Egrifta WR formulation and said the company wants a smooth switch for eligible patients from the older version.
Christian MarsolaisSourceRecommends
Money: Executive of the company that sells Egrifta
Led a 6-month trial in people with HIV and abdominal obesity. Waist size fell, but thinking and memory scores did not improve more than with standard care.
Ronald EllisWebsiteMixed view
Photo source: providers.ucsd.edu
More contextCase reports, watch and read, emerging uses and chemistry
Case reports
From journals, regulators and studies of users. One case proves little.
Harm reportednews-reported case - 1 person - 2026
A California man in his 40s bought tesamorelin informally from an acquaintance who sold peptides. Months later he collapsed after an injection, hit his head and was treated in hospital for a serious allergic reaction. The product was not lab tested.
Source: Forbes Brasil (Forbes feature by Iain Martin), 2026-09
Watch and read
Explainers, reporting and podcasts worth your time. Summaries are ours. No sellers.
How does Tesamorelin Work for HIV/AIDS Patients?
Dr Rob Swanda, science educator
A science educator explains how tesamorelin works in the body and why it was developed for excess abdominal fat in people living with HIV.
Covers the approved medical use, not the biohacking hype.
What the peptide craze reveals about Americans' relationship with risk
Sarah Todd, STAT reporter
Essay on why unproven peptides appeal to Americans, noting cancer-risk worries raised about growth hormone peptides such as tesamorelin and thin research behind newer ones.
Puts tesamorelin in the wider peptide safety debate.
When options run out
Uses people turn to when standard treatment has failed.
Fatty liver disease in HIV
- Who
- People with HIV and fatty liver, who have few proven drug options.
- Evidence
- One 61-person randomised trial: about a third reached normal liver fat after 12 months versus very few on placebo, and fewer had new or worse scarring. Not an approved use.
Source: NIH news release, 2019-10
Cognitive impairment in HIV with obesity
- Who
- Older adults with HIV, abdominal obesity and mild thinking problems.
- Evidence
- One open-label phase 2 trial of 73 virally suppressed adults: six months of treatment shrank waist size but gave no clear cognitive benefit over standard care.
Legal last-resort routes
Expanded access (compassionate use)
For a serious or life-threatening condition with no comparable alternative and no trial you can join. Your physician asks the company for the drug, then files with FDA and an ethics board. The company can refuse. Costs are often not insured.
Right to Try
For a life-threatening condition after approved options are exhausted and no trial is open to you. The drug must have finished Phase 1 and be in active development. Your doctor asks the manufacturer directly. FDA does not review requests.
Source: FDA, Right to Try
Trial finders
Search ClinicalTrials.gov by condition or drug name, check eligibility and call the listed site. ResearchMatch is a free NIH-funded registry that lets researchers find you. Discuss risks with your own clinician before enrolling.
Source: NIH, finding a clinical trial
Personal import for serious conditions
FDA may not object when a US citizen imports up to about three months of a drug for a serious condition with no effective US treatment, with written personal-use confirmation and a US doctor's details. It is discretion, not a right.
Source: FDA, personal importation
Patient-specific compounding
When the approved product cannot meet a specific need of an identified patient, a prescriber can order a compounded version from a licensed pharmacy. Lower price alone does not qualify. Ingredients must be pharmaceutical grade.
Amino-acid sequence
Questions people ask
Does tesamorelin work for weight loss?
It is not approved for weight loss, and the label says it is not for that. A few small trials outside HIV reported less deep belly fat, which counts only as early evidence.
What is tesamorelin approved for?
Only for excess belly fat in adults with HIV lipodystrophy, sold in the US as Egrifta WR. Deep abdominal fat fell 18% in one trial and 14% in another over 26 weeks, and it comes back after stopping.
What are the side effects of tesamorelin?
Injection-site reactions in about a quarter of people, joint pain and swelling from fluid. It raises IGF-1, which went well above the normal range in about a third of people in trials, and it can raise blood sugar.
Is tesamorelin approved outside the US?
The EU application was withdrawn in 2012, and no UK license was found.
Your notebook
Taking it? A ten-second daily check-in keeps a record of how you feel, to talk through with your clinician.
Sources
- Egrifta WR US prescribing information (DailyMed)
- Stanley et al. 2019: tesamorelin and liver fat in HIV
- EMA: Egrifta withdrawn application
- ArentFox Schiff: FDA letters to research-use-only vendors (Sep 2026)
Structure: PubChem